Oppenheimer (NYSE: OPY) raised their price target on shares of Myriad Genetics (NASDAQ: MYGN) to $29.00 in a research note issued on Wednesday. The firm currently has a “market perform” rating on the stock.
Other equities research analysts have also recently issued reports about the stock. Analysts at Mizuho raised their price target on shares of Myriad Genetics from $27.00 to $29.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Cowen upgraded shares of Myriad Genetics from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, April 20th. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Myriad Genetics in a research note to investors on Friday, February 10th. They now have a $25.00 price target on the stock.
Myriad Genetics remained flat at $26.45 during trading on Wednesday. Myriad Genetics has a 52-week low of $17.51 and a 52-week high of $27.00. The company has a market cap of $2.229 billion and a price-to-earnings ratio of 21.63.
The company last announced its quarterly results on Tuesday, May 1st. It reported $0.34 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.32 EPS by $0.02. The company’s quarterly revenue was up 26.8% on a year-over-year basis. Analysts expect that Myriad Genetics will post $0.33 EPS next quarter.
Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests.